Global Migraine Drugs Market 2016-2020

This market research report presents a detailed segmentation of the global migraine drugs market by treatment type (preventive and abortive), by therapeutic class (triptans, ergots, and others), and by geography (the Americas, APAC, and EMEA). The leading vendors in the market are Allergan, Endo, GlaxoSmithKline, Impax Laboratories, and Pfizer.

Overview of the global migraine drugs market

According to the migraine drugs industry anlaysis, Technavio’s market research analysts estimate this market to grow at a CAGR of more than 4% between 2016 and 2020. One of the primary drivers for this market is the growing awareness about migraine and its treatment options. Several organizations such as the American Headache and Migraine Association are coming up with awareness programs and are providing assistance to patients in order to spread awareness about the disease and other headache-related disorders. Owing to the growing incidence of migraine and the presence of high unmet needs in this market, several companies have started investing in the R&D of migraine drugs, which in turn will boost the growth prospects for this market during the forecast period.

The increasing need for new treatment options has led to the development of new devices such as antimigraine devices and headbands in the market. For instance, Cefaly Transcutaneous Electrical Nerve Stimulation device is an FDA approved device for migraine treatment. This device stimulates the trigeminal nerve by emitting electric currents and provides remission from migraine. According to the migraine drugs industry insights, increasing spending on new research activities and novel product innovations will accelerate the growth and development of this market over the next four years.

Segmentation by therapeutic class and analysis of the migraine drugs market

• Triptans
• Ergots

Based on the migraine drugs market outlook, Triptans are the largest segment of the global migraine drugs market, occupying around 84% of the total market share in 2015. Some of the available drugs in this segment include Almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. These medicines are formulated in various forms such as tablets, injections, and nasal spray preparations. The growing utilization of the oral route of administration (ROA) will augment the growth prospects for this segment in the coming years.

Geographical segmentation and analysis of the migraine drugs market

• Americas
• APAC
• EMEA

APAC will be the fastest-growing region in the migraine drugs market and is expected to grow at a CAGR of 6% by 2020. The primary reason for this reason’s growth is the increase in the number of people suffering from migraine and growing public awareness about the disease.  India and China are the major markets in this region as the prevalence of migraine are high in these countries. The growing focus on new product launches and the high penetration of drug manufacturers will aid in the growth of the market in APAC during the forecast period.

Competitive landscape and key vendors

At present, the market is growing at a slow pace because of the increased genericization of drugs. The market is also witnessing high unmet needs as there is no permanent cure for the disease. This has propelled vendors in the market to make huge investments in R&D. Several companies are expected to enter the market during the predicted period. Companies that manufacture and sell migraine drugs that exhibit a high safety and efficacy profile are expected to gain a competitive edge over their peers.

Key vendors in the market are 

• Allergan
• Endo
• GlaxoSmithKline
• Impax Laboratories
• Pfizer

The other prominent vendors in the migraine drugs market include Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Allergan, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy's Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, and Zogenix.

Key questions answered in the report include

• What will the migraine drugs market size and the growth rate be in 2020?
• What are the key factors driving the global migraine drugs market?
• What are the key migraine drugs market trends impacting the growth of the market?
• What are the challenges to market growth?
• Who are the key vendors in the global migraine drugs market?
• What are the market opportunities and threats faced by the vendors in the global migraine drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global migraine drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Pain Management Drugs Market 2016-2020
• Global Migraine Drugs Market 2015-2019